The CheckMate -816 trial shows nivolumab plus platinum-doublet chemotherapy significantly improves overall survival in ...

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales. In final guidance ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for an Opdivo (nivolumab) and Yervoy (ipilimumab) combo as a first ...

“The results continue to support [Opdivo plus Cabometyx] as a standard of care for previously untreated advanced RCC.” A total of 651 patients were enrolled in the trial and randomly assigned to ...

The Opdivo group showed a median EFS of almost 32 months, compared to around 21 months for the chemo arm, and there was also an increase in the pathologic complete response (pCR) rate, coming in ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal antibody Yervoy (ipilimumab ...

Participants were randomized to receive intravenous (IV) Opdivo or placebo at 240 mg every two weeks. They received adjuvant treatment for up to 1 year. Stratification factors included tumor PD-L1 ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...